Individualized management of thyroid cancer based on tumor risk stratification by genetic variation is now widely recognized, and molecular testing has evolved from single-gene BRAF testing to multi-locus analysis of multiple genes, such as gene fusions, single nucleotide polymorphisms, and copy number variants, suggesting that more in-depth multi-gene studies could be conducted in the future. The gene discussed is BRAF; the disease is neoplasm.